| 2025/17/12 - 07:30 |
|
ABIONYX Pharma carries out a capital increase with cancellation of preferential subscription rights in favor of certain categories of persons, amounting to approximately €1.8m
|
pdf
|
| 2025/16/12 - 20:12 |
|
ABIONYX Pharma is launching a capital increase with cancellation of preferential subscription rights in favor of certain categories of persons, amounting to approximately €1.8m
|
pdf
|
| 2025/25/11 - 18:16 |
|
ABIONYX Pharma reports on its business and cash position for the third quarter of 2025
|
pdf
|
| 2025/20/11 - 18:00 |
|
ABIONYX Pharma and SEBIA announce an exclusive global strategic partnership to transform sepsis diagnosis
|
pdf
|
| 2025/12/11 - 07:00 |
|
ABIONYX Pharma Announces Advanced Strategic Discussions with IHU SEPSIS, the World's Leading Center Dedicated to Sepsis
|
pdf
|
| 2025/21/10 - 18:02 |
|
ABIONYX Pharma Announces Landmark Validation: A Study published in NATURE Confirms Genetic Causality of Apolipoprotein A-I (ApoA-I) in Sepsis
|
pdf
|
| 2025/25/09 - 18:30 |
|
2025 Half-Year financial results
|
pdf
|
| 2025/28/08 - 19:00 |
|
ABIONYX Pharma provides an update on its activity and cash position for the 2nd quarter 2025
|
pdf
|
| 2025/27/08 - 19:37 |
|
ABIONYX Pharma announces the start of discussions with a major player in the field of sepsis for a strategic partnership
|
pdf
|
| 2025/27/06 - 19:00 |
|
ABIONYX Pharma announces approval of all resolutions put to the vote at its Combined General Meeting
|
pdf
|
| 2025/28/05 - 18:00 |
|
ABIONYX Pharma provides an update on its activity and cash position for the 1st quarter 2025
|
pdf
|
| 2025/06/05 - 20:01 |
|
Monthly statement of total voting rights and shares forming the company’s share capital
|
pdf
|
| 2025/21/03 - 07:30 |
|
CIC Market Solutions initiates buy coverage of ABIONYX Pharma
|
pdf
|
| 2025/17/03 - 18:00 |
|
Availability of the Universal Registration Document for the year 2024
|
pdf
|
| 2025/05/03 - 07:30 |
|
ABIONYX Pharma announces its 2024 full-year results
|
pdf
|
| 2025/28/02 - 07:30 |
|
World Rare Disease Day: ABIONYX renews its commitment to treat LCAT Deficiency (Norum's disease) and provides an update on its advances
|
pdf
|
| 2025/27/02 - 19:04 |
|
ABIONYX Pharma provides an update on its business and cash position for the 4th quarter of 2024
|
pdf
|
| 2025/20/02 - 07:30 |
|
ABIONYX Pharma, winner of the France 2030 Plan’s “i-Démo” call for projects, awarded €8.7 million from the French government to fight against Sepsis, the 3rd leading cause of death worldwide
|
pdf
|
| 2025/13/01 - 18:00 |
|
ABIONYX Pharma announces its financial calendar for the year 2025
|
pdf
|
